VISEN Pharmaceuticals disclosed a repurchase of 7,300 ordinary shares on 18 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The buybacks were executed within a price range of HK$19.41–HK$20.10 per share, translating to a volume-weighted average cost of HK$19.54 and an aggregate consideration of HK$0.14 million.

Following the transaction, VISEN’s issued share capital (excluding treasury shares) declined to 113.77 million shares from 113.77 million, while total issued shares, including treasury stock, remained unchanged at 113.93 million. Treasury shares held by the company increased to 160,400, all of which represent shares repurchased since the current mandate—authorising up to 11.39 million shares—was approved on 27 June 2025. Cumulative repurchases under this mandate now equal 160,400 shares, equivalent to 0.14% of the company’s issued shares at the authorisation date.

In accordance with Hong Kong listing rules, VISEN is subject to a 30-day moratorium on new share issues or sales of treasury shares, effective until 18 July 2026. The board confirmed that the repurchase complied with all regulatory requirements and that all necessary authorisations and filings have been duly completed.